SEC Company Response from Tvardi Therapeutics, Inc. (TVRD) (CIK 0001346830) (TVRD) — Jan 28, 2014
Tvardi Therapeutics, Inc. (TVRD) (CIK 0001346830)
Date: Jan. 28, 2014 · CIK: 0001346830 · Accession: 0001193125-14-023830
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-192230
Letter
Company Acceleration Request
1 Parrott Drive
Shelton, Connecticut
VIA EDGAR
January 28, 2014
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 4720
Washington, D.C. 20549
Attn: Mr. Jeffrey P. Riedler
Mr. Scot Foley
Mr. Bryan J. Pitko
Ms. Ibolya Ignat
Mr. Andrew Mew
Re: Cara Therapeutics, Inc.
Registration Statement on Form S-1
File No. 333-192230
Acceleration Request
Requested Date:
Thursday, January 30, 2014
Requested Time:
4:00 P.M. Eastern Standard Time
Ladies and gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective on January 30, 2014, at 4:00 p.m., Eastern Standard Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the “Staff”). The Registrant hereby authorizes each of Babak Yaghmaie, Darren DeStefano and Hosea Chang of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Hosea Chang of Cooley LLP, counsel to the Registrant, at (703) 268-8220.
In connection with this request, the Registrant acknowledges that:
•
should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
Cara Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm Company Acceleration Request 1 Parrott Drive Shelton, Connecticut 06484 VIA EDGAR January 28, 2014 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4720 Washington, D.C. 20549 Attn: Mr. Jeffrey P. Riedler Mr. Scot Foley Mr. Bryan J. Pitko Ms. Ibolya Ignat Mr. Andrew Mew Re: Cara Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-192230 Acceleration Request Requested Date: Thursday, January 30, 2014 Requested Time: 4:00 P.M. Eastern Standard Time Ladies and gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective on January 30, 2014, at 4:00 p.m., Eastern Standard Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the “Staff”). The Registrant hereby authorizes each of Babak Yaghmaie, Darren DeStefano and Hosea Chang of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Hosea Chang of Cooley LLP, counsel to the Registrant, at (703) 268-8220. In connection with this request, the Registrant acknowledges that: • should the Commission or the Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Registrant may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Very truly yours, Cara Therapeutics, Inc. By: /s/ Derek Chalmers Derek Chalmers Chief Executive Officer cc: Babak Yaghmaie, Cooley LLP Darren DeStefano, Cooley LLP Stephane Levy, Cooley LLP Hosea Chang, Cooley LLP Peter N. Handrinos, Latham & Watkins LLP